INmune Bio (NASDAQ:INMB) Price Target Raised to $23.00 at Scotiabank

INmune Bio (NASDAQ:INMB) had its price target upped by Scotiabank from $22.00 to $23.00 in a report published on Tuesday,Benzinga reports. The firm currently has a sector outperform rating on the stock.

INMB has been the topic of several other research reports. Alliance Global Partners initiated coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price target on the stock. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on INmune Bio in a research report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $22.80.

INmune Bio Stock Up 1.9 %

INmune Bio stock opened at $9.30 on Tuesday. The company has a market capitalization of $206.18 million, a P/E ratio of -4.27 and a beta of 1.87. The stock’s 50 day moving average is $6.44 and its 200 day moving average is $6.11. INmune Bio has a twelve month low of $4.32 and a twelve month high of $14.74.

Hedge Funds Weigh In On INmune Bio

Several hedge funds and other institutional investors have recently modified their holdings of INMB. Raymond James Financial Inc. bought a new position in shares of INmune Bio during the 4th quarter valued at $2,221,000. Praetorian PR LLC lifted its holdings in shares of INmune Bio by 61.0% during the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after buying an additional 295,800 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of INmune Bio by 73.3% during the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock valued at $868,000 after buying an additional 78,600 shares during the period. State Street Corp lifted its holdings in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after buying an additional 58,838 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of INmune Bio during the 3rd quarter valued at $249,000. 12.72% of the stock is owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.